← Back to Analyst Consensus 
CRDF Buy
Cardiff Oncology, Inc.
Current Price —
Implied Upside —
Analysts 12
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Oct 29, 2026 (3 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 15, 2026 | HC Wainwright & Co. | upgrade | Neutral → Buy | — | 44% |
| Aug 12, 2026 | William Blair | downgrade | Outperform → Market Perform | — | 48% |
| Jun 3, 2026 | Craig-Hallum | downgrade | Buy → Hold | — | 54% |
| Jun 1, 2026 | TD Cowen | downgrade | Buy → Hold | — | 54% |
| Jun 1, 2026 | HC Wainwright & Co. | downgrade | Buy → Neutral | — | 44% |
| Feb 25, 2026 | Piper Sandler | maintain | Overweight → Overweight | $6 | 54% |
| Jan 28, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Aug 6, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $10 | 44% |
| Jul 8, 2025 | Ladenburg Thalmann | initiate | — → Buy | $19 | 45% |
| Jun 24, 2025 | Jefferies | initiate | — → Hold | $3.5 | 52% |
| May 9, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $18 | 44% |
| Feb 28, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $17 | 44% |
| Dec 13, 2024 | Piper Sandler | maintain | Overweight → Overweight | $10 | 54% |
| Nov 8, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $13 | 44% |
| Sep 6, 2024 | Craig-Hallum | initiate | — → Buy | $8 | 54% |
| May 6, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $14 | 44% |
| Mar 6, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $14 | 44% |
| Mar 1, 2024 | Piper Sandler | maintain | Overweight → Overweight | $7 | 54% |
| Aug 11, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $12 | 44% |
| Aug 8, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $13 | 44% |
| May 9, 2023 | HC Wainwright & Co. | maintain | — → Buy | $14 | 44% |
| Mar 29, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $15 | 44% |
| Mar 7, 2023 | HC Wainwright & Co. | maintain | — → Buy | $15 | 44% |
| Sep 16, 2022 | HC Wainwright & Co. | maintain | — → Buy | $14 | 44% |
| Sep 13, 2022 | Piper Sandler | maintain | — → Overweight | $5 | 54% |
| Aug 29, 2022 | Baird | maintain | — → Outperform | $6 | 55% |
| May 9, 2022 | HC Wainwright & Co. | maintain | — → Buy | $22 | 44% |
| Feb 28, 2022 | HC Wainwright & Co. | maintain | — → Buy | $25 | 44% |
| Dec 8, 2021 | Baird | initiate | — → Outperform | $19 | 55% |
| Aug 10, 2021 | HC Wainwright & Co. | maintain | — → Buy | $26 | 44% |
| May 10, 2021 | HC Wainwright & Co. | maintain | — → Buy | $25 | 44% |
| Oct 22, 2020 | HC Wainwright & Co. | initiate | — → Buy | $27 | 44% |
| Oct 8, 2020 | Piper Sandler | initiate | — → Overweight | $25 | 54% |
| Sep 18, 2020 | Maxim Group | maintain | — → Buy | $14 | 42% |
Price Target Trend
Apr 22, 2026 Latest: $6.28 Oct 24, 2026
EPS Estimates
0q $-0.13
Lo: $-0.14 Hi: $-0.12
4 analysts ▲4
0y $-0.56
Lo: $-0.60 Hi: $-0.50
4 analysts ▲4
+1q $-0.14
Lo: $-0.20 Hi: $-0.09
5 analysts ▲1
+1y $-0.54
Lo: $-0.76 Hi: $-0.33
4 analysts ▲4
Cross-Platform Signals
No cross-platform signals in the last 90 days